Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-HAP toothpaste is a topical dental formulation containing nanohydroxyapatite (nano-HAP), a synthetic mineral that is chemically and structurally similar to natural tooth enamel and dentin. Developed by the University of Texas Health Science Center at San Antonio (UTHSA) in collaboration with SANGI Co., Ltd., the product is primarily indicated for the relief of dentin hypersensitivity (DHS). Its mechanism of action involves the physical occlusion of exposed dentinal tubules and the remineralization of the tooth surface, thereby preventing external stimuli from reaching the dental pulp and reducing pain. Clinical evaluation, including a randomized Phase 2 trial (NCT02918617), has demonstrated that formulations containing 10% or 15% nano-HAP are effective in reducing sensitivity, showing comparable efficacy to other desensitizing technologies such as calcium sodium phosphosilicate (NovaMin).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nanohydroxyapatite (UT Health San Antonio).